Second Genome CEO and leadership

President, CEO and member of the Board of Directors at Second Genome. Karim joined Second Genome in 2014 as the CSO and acted in that role until 2018. Previously, Karim led the immunoregulation department at Pfizer, an R&D group focused on innovative approaches to elicit homeostatic immune responses for the treatment of immune related disorders. In addition, Karim led external R&D innovation for autoimmune and inflammatory diseases. Prior to joining Pfizer, he was the founder of Modus BioMedicine, a start-up biotechnology company focused on treatments for transplantation and autoimmune disease. Before that, he spent nine years at Roche Pharmaceuticals in multiple positions, including Head of Inflammation Discovery Research Pharmacology. Karim received his doctorate in biochemistry from University College, London, and completed postdoctoral fellowships at the Cardiovascular Research Institute at University of California, San Francisco, and at Stanford University. He received a bachelor’s degree in biotechnology from the Imperial College of Science, Technology and Medicine in London. He also attended Université Claude Bernard Lyon I in France after obtaining his French Baccalaureate (Section D) from the Lycée Français Charles de Gaulle in Ankara. Karim is a French-American dual citizen. Specialties: Pharmaceutical R&D (pre-clinical to phase 2) in inflammation/immunology, pulmonary and autoimmune diseases and transplantation.R&D Management, executive leadership, Business development, new company start-up, product spin-out.

Susannah Cantrell is a Chief Business Officer at Second Genome Inc and is based in South San Francisco, California. She has experience at Roche and has worked as VP & Head:Global Commercial Strategy & Mktg Oncology at GILEAD SCIENCES INC; Regional Medical Scientist (Medical Affairs) at GSK; and Senior VP/Chief Commercial Ofcr at Tricida, Inc.. Susannah attended University of Missouri-Columbia between 1994 and 1998 and Westminster College between 1988 and 1991.

President, CEO and member of the Board of Directors at Second Genome. Karim joined Second Genome in 2014 as the CSO and acted in that role until 2018. Previously, Karim led the immunoregulation department at Pfizer, an R&D group focused on innovative approaches to elicit homeostatic immune responses for the treatment of immune related disorders. In addition, Karim led external R&D innovation for autoimmune and inflammatory diseases. Prior to joining Pfizer, he was the founder of Modus BioMedicine, a start-up biotechnology company focused on treatments for transplantation and autoimmune disease. Before that, he spent nine years at Roche Pharmaceuticals in multiple positions, including Head of Inflammation Discovery Research Pharmacology. Karim received his doctorate in biochemistry from University College, London, and completed postdoctoral fellowships at the Cardiovascular Research Institute at University of California, San Francisco, and at Stanford University. He received a bachelor’s degree in biotechnology from the Imperial College of Science, Technology and Medicine in London. He also attended Université Claude Bernard Lyon I in France after obtaining his French Baccalaureate (Section D) from the Lycée Français Charles de Gaulle in Ankara. Karim is a French-American dual citizen. Specialties: Pharmaceutical R&D (pre-clinical to phase 2) in inflammation/immunology, pulmonary and autoimmune diseases and transplantation.R&D Management, executive leadership, Business development, new company start-up, product spin-out.